Semantic Scholar uses AI to extract papers important to this topic.
We have developed MGD007 (anti-glycoprotein A33 x anti-CD3), a DART protein designed to redirect T cells to target gpA33… Expand In recent reports, we have shown that optimized pretargeted radioimmunotherapy (PRIT) based on molecularly engineered antibody… Expand Radioimmunotherapy of solid tumors using antibody-targeted radionuclides has been limited by low therapeutic indices (TIs). We… Expand PurposeGPA33 is a colorectal cancer (CRC) antigen with unique retention properties after huA33-mediated tumor targeting. We… Expand The secretopeptidome comprises endogenous peptides derived from proteins secreted into the tumour microenvironment through… Expand A single-chain fusion protein that directed the cytolytic activity of α-sarcin to A33 tumor antigen expressing cells was… Expand Within the last 10 years, the use of different RNases as therapeutic agents for various diseases has been pursued. Furthermore… Expand The glycoprotein A33 (GPA33) is a colon cancer antigen. Phase I trials with 131I and 125I monoclonal antibody A33 in colon… Expand Essential hypertension is a major cardiovascular risk factor and a large proportion of this risk is genetic. Identification of… Expand Analysis of epitopes for the three monoclonal antibodies (GPA105, GPA33, OSK4-1) against glycophorin A (GPA) was performed with… Expand